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Background: This study aimed to explore the potential association 
of mutation in the epidermal growth factor receptor (EGFR) with 
brain metastases in patients with pulmonary adenocarcinoma.
Methods: We analyzed clinical data on 314 patients who were tested 
for EGFR mutation and underwent brain magnetic resonance imag-
ing at diagnosis. The relationship between EGFR mutation status and 
brain metastases at the initial presentation was analyzed. In addition, 
prognostic significance of EGFR mutational status on the risk of brain 
metastasis was evaluated in subgroups of surgically treated patients.
Results: Of the 314 patients, 138 patients (43.9%) had EGFR muta-
tions. The frequency of EGFR mutation was statistically higher for 
patients with brain metastases (64.7%, brain metastases; 39.8%, no 
metastases; 40.2%, extracranial metastases; p = 0.005). A strong 
association between EGFR mutation status and brain metastasis was 
observed (adjusted odds ratio = 3.83, p = 0.001), whereas no asso-
ciation was observed between EGFR mutation status and extracra-
nial metastases (adjusted odds ratio = 1.73, p = 0.079). In addition, 
the number of brain metastases was significantly correlated with the 
EGFR mutation status (p = 0.029). Further analysis of 133 patients 
treated with surgical resection showed that EGFR mutation status 
was a poor prognostic factor for the risk of brain metastasis (hazard 
ratio = 4.49, p = 0.026) after adjustment for pathologic N stage.
Conclusions: We found a significant association between EGFR 
mutation and risk of brain metastases at the time of diagnosis and 
follow-up after curative resection for pulmonary adenocarcinoma. 
This result indicates the distinct clinical features of EGFR-mutated 
tumors in terms of brain metastases.
Key Words: Epidermal growth factor receptor mutation, Pulmonary 
adenocarcinoma, Brain metastasis, Cranial metastasis.
(J Thorac Oncol. 2014;9: 195–199)
Lung cancer is the leading cause of cancer death world-wide,1,2 and extensive research on this cancer has been 
conducted to date. Recent progress in the field of medi-
cal treatment of advanced lung cancer has been focusing on 
molecular changes.
Genetic alteration of the epidermal growth factor 
receptor (EGFR), which is predominantly found in ade-
nocarcinomas,3 is a representative marker in determining 
the appropriate treatment for advanced lung cancer.3,4 The 
recognition of EGFR mutation indicates clinical treat-
ment with tyrosine kinase inhibitors such as gefitinib and 
erlotinib.5–7
Among distant metastases, brain metastasis is one of 
the most devastating complications of lung cancer threaten-
ing affected patients.8 Although magnetic resonance imaging 
(MRI) is used to detect brain metastases, its cost effective-
ness remains uncertain.9 Moreover, there is controversy over 
the use of routine brain MRI in staging asymptomatic patients 
with non–small-cell lung cancer (NSCLC), particularly when 
they have early thoracic diseases.10,11 Thus, in studies of brain 
metastases, potential biases arise from overlooking patients 
with brain metastases.
Extensive research has proved the association between 
the genetic alteration of EGFR and distant metastases in 
various cancers such as those of the breast and rectum.12–14 
In patients with pulmonary adenocarcinomas, different pul-
monary metastatic patterns of EGFR-mutated tumors were 
also reported.15 However, because of the limited data avail-
able, it has not been possible to determine different brain 
metastases according to EGFR mutation status in pulmonary 
adenocarcinomas.
Several studies have tried to identify the predic-
tive factors for brain metastasis in patients with NSCLC. 
Carcinoembryonic antigen,16 size of primary tumor, nodal 
stage,17 and presence of bone metastases18 have been 
proposed as predictive factors for the presence of brain 
metastasis in patients with NSCLC. A histopathology of 
nonsquamous cell carcinoma is also known to be a predic-
tive factor, which means that pulmonary adenocarcinoma 
has a higher tendency to metastasize to the brain than squa-
mous cell carcinoma.17 However, the clinical implications 
of EGFR mutation status in terms of brain metastasis in 
patients with pulmonary adenocarcinoma have not yet been 
examined.
In this study, we investigated the clinical association 
between EGFR mutation and brain metastasis in patients with 
pulmonary adenocarcinoma who were examined by using 
brain MRI.
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PATIENTS AND METHODS
Patients
A total of 314 patients diagnosed with adenocarcinoma 
of the lung were consecutively enrolled between October 2005 
and December 2011 at the Korea Cancer Center Hospital. We 
evaluated the patients’ data from chest computed tomography 
(CT) scan, bone scan, and MRI of brain, as routine staging 
workup, for which expenses were shared by national health 
insurance. The tumor stage was classified using recently 
revised tumor, node, metastasis (TNM) system proposed by 
American Joint Committee on Cancer (8th edition). T and N 
stage were determined on the basis of the findings of CT with 
or without additional fiberoptic bronchoscopy. Mediastinal 
lymph nodes larger than 1 cm on transaxial CT images were 
considered positive. Stage was not based on the findings of 
additional positron emission tomography scan because it was 
not performed in all patients. Distant metastases were cat-
egorized as metastasis to the brain and those to extracranial 
sites only. Patients with squamous cell and adenosquamous 
carcinoma were excluded. Recurrence of brain metastases in 
patients who had been treated with curative resection were 
suspected on the basis of clinical symptoms and confirmed by 
results of brain MRI.
EGFR Genotyping
Genomic DNA was extracted from paraffin-embedded 
tissues, as described previously.19 In patients whose only 
available tissue was cytologic sample at initial diagnosis, 
 methanol-fixed cytologic specimens were used for DNA 
extraction.20 EGFR mutation analysis was carried out by direct 
sequencing before March 2009 (135 patients), and pyrose-
quencing was performed for the detection of EGFR mutation 
after March 2009 (179 patients), as described previously.21
Statistical Methods
Statistical analysis of data was performed using STATA 
version 11 (Stata Corp, College Station, TX). The associa-
tions between EGFR mutation status and clinical features, 
specifically age, sex, smoking, TNM stage, and metastatic 
site, as well as brain metastasis, were analyzed using logistic 
regression analysis. Clinical factors known to be associated 
with EGFR mutation status in pulmonary adenocarcinoma 
and staging factors of TNM were included in the multivariate 
analysis.
The associations between the spread pattern of brain 
metastases and EGFR mutation status were also evaluated 
using Kruskal–Wallis test. The prognostic implications of 
EGFR mutation on the occurrence of brain metastasis in 
patients who were treated with surgical resection were ana-
lyzed using competing risk regression analysis of Fine and 
Gray.22 Deaths without cranial disease were considered as 
competing events. A p value less than 0.05 (two-sided) was 
considered statistically significant.
Ethics
This study protocol was reviewed and approved by 
the Institutional Review Board of the Korea Cancer Center 
Hospital (Insititutional Review Board No: K-1206-002-030). 
The recommendations of the Declaration of Helsinki for bio-
medical research involving human subjects were followed.
RESULTS
Patient Characteristics
A total of 314 patients (151 men and 163 women) with 
a median age of 64 years (range, 25–84 years) were consec-
utively enrolled in our study. Adenocarcinoma was the his-
tologic subtype in all patients. Almost half of the patients 
(153 patients, 48.7%) had metastatic disease. Among the 153 
patients with distant metastases, 51 patients (33.3%) had cra-
nial metastases and 102 patients (66.7%) had only extracranial 
metastases (Table 1).
A total of 138 patients (43.9%) had mutations, of which 
exon 19 deletion was the most common (79 patients, 57.2%), 
followed by L858R mutation in exon 21 (51 patients, 37.0%). 
The other eight patients (5.8%) had a G719X  mutation in 
exon 18.
EGFR Mutation and Baseline Characteristics
In univariate analysis, EGFR mutation was found more 
frequently in women (61.4% versus 25.2% [men], p < 0.001) 
and never smokers (60.6% versus 26.6% [ smokers], 
p < 0.001). The difference in age according to EGFR muta-
tion (64 years versus 61 years [wild type], p = 0.12) was not 
statistically significant.
We further evaluated the association between stage and 
EGFR mutation. A reverse correlation between advanced 
nodal stage and EGFR mutation was observed (36.2% [N2–3] 
versus 47.9% [N0–1]). However, statistical significance was 
marginal in univariate analysis (p = 0.050). The frequency 
of EGFR mutation did not differ by T stage (44.7% [T1–2] 
versus 41.4% [T3–4], p = 0.63), whereas the size of primary 
tumor was inversely correlated with EGFR mutation (3.0 cm 
versus 3.4 cm [wild type], p = 0.024) (Table 1). Metastatic dis-
ease (M1) was not associated with EGFR mutation in univari-
ate analysis (39.8% [M0] versus 48.4% [M1], p = 0.12).
TABLE 1.  Baseline Characteristics (N = 314)
EGFR Mutation
p  
Value
Positive 
(n,%)
Negative 
(n,%)
Age (median, range), years 63 (25–84) 61(35–82) 0.18
Sex, n (%) Male 38 (25.2) 113(74.8) <0.001
Female 100 (61.4) 63(38.7)
T stage 1–2 109 (44.7) 135 (55.3) 0.63
3–4 29(41.4) 41 (58.6)
N stage 0–1 100(47.9) 109(52.2) 0.05
2–3 38(36.2) 67(63.8)
Distant metastasis No 64(39.75) 97(60.25) 0.005
Craniala 33(64.7) 18(35.3)
Extracranial 41(40.2) 61(59.8)
aInclusion of 44 patients with extracranial metastases.
EGFR, epidermal growth factor receptor.
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EGFR Mutation and Brain Metastasis 
in Multivariate Analysis
At the time of initial diagnosis of pulmonary adenocar-
cinoma, the frequency of EGFR mutations was statistically 
different according to the site of metastases (39.8% [no metas-
tases] versus 40.2% [extracranial metastases] versus 64.7% 
[brain metastases], p = 0.005). The percentage of EGFR muta-
tions was also significantly different in subcohorts of meta-
static disease (40.2% [extracranial metastases] versus 64.7% 
[brain metastases], p = 0.004).
Next, we assessed the significance of EGFR mutation 
with respect to brain metastases by using the multivariate 
model. A strong association between EGFR mutation status 
and brain metastasis was observed (adjusted odd ratio = 3.83, 
95% confidence interval [CI]: 1.72–8.55, p = 0.001), whereas 
there was no association between EGFR mutation and 
extracranial metastases (adjusted odd ratio = 1.73, 95% CI: 
0.94–3.20, p = 0.079) (Table 2). In the final model, nodal stage 
(p = 0.025) and tumor size (p = 0.024) remained significant 
factors, whereas smoking history was no longer significant 
(p = 0.088).
EGFR Mutation and Physical Features 
at Metastatic Brain Lesion
To investigate the potential difference in physical fea-
tures of brain metastases according EGFR mutation, we per-
formed a subgroup analysis in patients with brain metastases 
(n = 51). The number and size of brain metastases stratified 
by EGFR mutation status are described in detail in Table 3. 
Multiple brain metastases (≥2 metastatic lesions) were more 
frequently detected in EGFR-mutated tumors than in EGFR 
wild-type tumors (78.6% versus 47.8%, p = 0.022). In addi-
tion, the number of brain metastases according to EGFR 
mutation status showed a statistical significance (p = 0.029). 
However, the size of the largest metastatic brain lesion was not 
significantly different according to EGFR mutation status, in 
contrast with the primary tumor size (Table 3).
Risk of Brain Metastasis after Surgical Resection
To evaluate prognostic significance of EGFR muta-
tion status with respect to brain metastases, we performed a 
subgroup analysis for the risk of brain metastasis in patients 
who were treated with curative resection of pulmonary 
adenocarcinoma (133 patients). The last follow-up review 
of this group of patients was done on January 2, 2013. The 
median follow-up duration in this cohort was 28.6 months 
(range, 0.3–74.4). The recurrent brain metastases suspected 
on the basis of clinical symptoms during follow-up period 
were confirmed by performing brain MRI. To reach a con-
crete conclusion, the pathologic N stage was included in 
the final multivariate analysis. Brain metastases were devel-
oped in a total of 10 patients among 133 patients who were 
treated with curative resection. Deaths without cranial dis-
ease (n=17) were considered as competing events. Our result 
showed that EGFR-mutant tumor had a significantly higher 
risk of recurrence of brain metastasis (hazard ratio = 4.49, 
95% CI: 1.20–16.80, p = 0.026) adjusted by pathologic N 
stage (0–1 versus 2, hazard ratio =4.75, 95% CI: 1.37–16.49, 
p = 0.014) (Fig. 1).
DISCUSSION
In this study, we evaluated different features of brain 
metastases according to EGFR mutation status. To exclude 
the impact of histology, this study was confined to data on 
pulmonary adenocarcinoma. Of note, the risk of brain metas-
tases increased in EGFR-mutated tumors at the time of diag-
nosis as well as during disease course after surgery. Compared 
with wild-type tumors, EGFR-mutated tumors showed wide 
spread of brain lesions. To date, there have been few stud-
ies that focused on the implications of EGFR mutation on 
brain metastasis in a homogeneous population of pulmonary 
adenocarcinomas.
This is the first study to suggest that EGFR mutation 
is significantly associated with a higher likelihood of brain 
metastases in patients with pulmonary adenocarcinomas at 
initial presentation. Some investigators have shown clinical 
evidence for the impact of EGFR mutation on distant metas-
tasis. Preliminary results from a Chinese study suggested dif-
ferent metastatic patterns in the brain.23 In contrast, in another 
study evaluating three different oncogenes (EGFR, V-Ki-
ras2 Kirsten rat sarcoma viral oncogene homolog [KRAS], 
and anaplastic lymphoma receptor tyrosine kinase [ALK]),24 
EGFR mutation was not significantly associated with brain 
metastasis.24 However, different diagnostic timing of meta-
static presentation and histological heterogeneity in the previ-
ous studies23,24 should be considered. It seems difficult to draw 
TABLE 2.  Clinical Features Related to EGFR Mutation Status 
in Patients with Lung Adenocarcinoma
Multivariate
Odds Ratio (95% Confidence 
Interval) p Value
Sex 2.86 (1.40–5.87) 0.004
Smoking
Sizea
0.54 (0.26–1.10)
0.83 (0.71–0.98)
0.088
0.024
T (T3/4) 1.46 (0.71–3.01) 0.30
N (N2/3) 0.50 (0.27–0.91) 0.025
M (M1) Cranial 3.83 (1.72–8.55) 0.001
Extracranial 1.73 (0.94–3.20) 0.079
aContinuous variable.
EGFR, epidermal growth factor receptor.
TABLE 3.  Characteristics of Brain Metastases  according 
to EGFR Mutation Status in Patients with Pulmonary 
Adenocarcinoma with Brain Metastasis (n = 51)
Brain Metastases
EGFR Mutation Status
p ValuePositive (n = 33) Negative (n = 18)
Number (median, range) 5 (1–57) 2 (1–21) 0.029a
Sizeb (median, range) 1.2 (0.3–4.3) 0.9 (0.4–5.0) 0.44a
aKruskal–Wallis test.
bSize of the largest brain metastasis in centimeters.
EGFR, epidermal growth factor receptor.
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conclusions from previous data about the clinical implication 
of EGFR mutation on brain metastases.23,24
Further analysis of data from patients with brain metas-
tases showed that EGFR mutation was significantly associated 
with extended tumor spread in terms of the number of brain 
metastases. However, the size of brain metastases was not 
associated with EGFR mutation status, neither were the spe-
cific subtypes of EGFR mutations correlated with the number 
and size of brain metastases (data not shown). In contrast with 
our study, Sekine et al.25 proposed that the miliary spread to 
the brain might be correlated with exon 19 deletion rather than 
exon 21 point mutation. Compared with the previous study,25 
our study had a different patient population. Our study popu-
lation consisted of patients with pulmonary adenocarcinoma, 
and we collected data from patients who received routine 
brain MRI, minimizing a potential bias from using different 
methods for brain imaging.
Of interest, the increased risk of brain metastases in 
EGFR-mutated tumors was also observed at the time of 
 follow-up after resection. It is well known that tumors with 
adenocarcinoma histology, in general, have a higher tendency 
of brain metastasis than lung cancer involving other cell types 
such as squamous cell carcinoma.17,26 However, data on the 
potentially prognostic role of EGFR mutation with respect 
to recurrence in the brain in resected patients are limited. 
Although the limitation of this study, its retrospective nature, 
cannot exclude a potential bias during the disease course 
under treatment, we believe that the prognostic impact of 
EGFR mutation on brain metastases is worth examining in 
further studies.
In our data, associations of EGFR mutations with pri-
mary tumor size and nodal stage, in addition to smoking 
history and sex, were suggested. In a previous study, EGFR 
mutations were predominantly seen in smaller primary 
tumors.27 The negative correlation between EGFR mutation 
status and advanced nodal stage is also consistent with find-
ings from a recent study.28 Considering the result that fre-
quent metastases to the brain are expected in large primary 
tumors and advanced nodal stages,17 the association between 
brain metastases and EGFR mutations cannot be explained by 
tumor extent only. Rather, it is likely that metastatic prefer-
ence to the brain may result from a distinct molecular pathway 
in EGFR-mutated tumors.
The molecular aspect explaining the link between 
EGFR mutation and brain metastases is unknown. However, 
the data from several studies let us infer possible hypotheses 
explaining why EGFR mutation–harboring pulmonary adeno-
carcinomas easily metastasize to the brain. An experimental 
study from China29 showed that EGFR inhibition significantly 
decreased brain metastases in a brain-trophic clone of human 
DMA-MB-231 breast carcinoma cell line. That study iterated 
that the action of EGFR in brain metastasis might be through 
phosphoinositide 3-kinase/protein kinase B and phospholi-
pase C γ downstream pathways. Another report performed by 
Benedettini et al.30 showed that Met expression and phosphory-
lation induced by gefitinib treatment were also associated with 
development of late brain metastasis in patients with NSCLC, 
indicating that potential role of another genetic change such as 
Met activation or a modification of the downstream signaling 
pathway below EGFR on brain metastases. Further clinicomo-
lecular studies need to performed to examine this further.
Our study has several limitations. First, the retrospective 
nature of our study was one of the potential pitfalls. Second, 
we could not evaluate other clinically important genetic 
changes besides EGFR mutations, for example, KRAS muta-
tion, Met amplification, or echinoderm microtubule-associ-
ated  protein-like 4 anaplastic lymphoma kinase translocation. 
Despite these limitations, our study is valuable in view of new 
insights about the clinical association between EGFR mutation 
status and brain metastasis in pulmonary adenocarcinoma.
Because of the devastating outcomes of brain metasta-
ses,8 the results of our study theoretically support the idea that 
physicians should pay attention to brain metastases, particu-
larly in patients with EGFR-mutated pulmonary adenocarci-
noma. Considering the uncertainty of cost effectiveness of 
brain MRI,9 EGFR mutations may be useful for early detec-
tion of brain metastases. However, its predictive role should 
be determined through further studies.
In conclusion, this study suggests an association between 
EGFR mutation and increased risk of brain metastases at the 
time of diagnosis and during the disease course after curative 
resection. Despite its retrospective nature being a limitation, 
this study is the first to indicate distinct clinical features of 
EGFR-mutated tumors in terms of brain metastases. Molecular 
studies should be conducted on this finding in the future.
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